DCGI approves clinical trials of Biological E. Covid-19 vaccine CORBEVAX on children
The Hindu
It has also received nod for conducting Phase III trial in adults
Hyderabad-based pharmaceutical firm Biological E. has for initiating the Phase II/III study to evaluate its CORBEVAX vaccine in children aged above 5 years. It has also received nod for conducting Phase III trial in adults after a Subject Expert Committee’s (SEC) review of its Phase I and II clinical trials data, a PIB release stated on September 3. Supported by the Department of Biotechnology, Biological E. has developed CORBEVAX, a RBD protein sub-unit vaccine for coronavirus disease.More Related News